Early acute toxicities associated with radiotherapy (RT) can compromise cancer treatment and, in the most extreme cases, lead to radiotherapy discontinuation. Predicting these toxicities is therefore a medical, social and economic challenge. Among the various factors involved in these toxicities, such as clinical and/or dosimetric factors, it is currently accepted that a large part of the risk of toxicity is due to individual radiosensitivity. 

This makes radiosensitivity prediction tests a valuable decision-making tool, whether for the choice of fractionation, therapeutic modality (e.g. surgery) or type of radiation (protons vs. photons). In recent years, many teams have tried unsuccessfully to implement radiosensitivity predictive tests in clinical routine.